Dr Rehan Haidry and his European colleagues have created the world’s largest registry of patients undergoing Transoral Incisionless Fundoplication (TIF).
The registry, called EURO‑TIF, represents a landmark achievement in the field of minimally invasive reflux therapy and is now entering its final phase of analysis, with results expected to be published in 2026.
Coordinated through Cleveland Clinic London (CCL‑2021‑TIF) and involving seven leading European centres, EURO‑TIF is the most comprehensive dataset outside North America evaluating the safety, efficacy and long‑term outcomes of both TIF and cTIF. This work reflects a major collaborative effort between interventional endoscopists and foregut surgeons across Europe.
A major step forward for TIF evidence
TIF is an endoscopic procedure that reconstructs the oesophageal flap valve using the EsophyX device. It is endorsed by the American Society for Gastrointestinal Endoscopy as a mechanical treatment option for patients with proven gastro‑oesophageal reflux disease (GORD).
Until now, Europe has lacked large‑scale, long‑term data on TIF outcomes. EURO‑TIF fills that gap by prospectively collecting detailed information from every patient undergoing TIF since 2021, including Reflux‑specific quality of life (QoL) scores, reduction or discontinuation of acid‑suppressing medication and procedural outcomes.
With 24‑month follow‑up, EURO‑TIF will provide the most robust European evidence to date on the durability and safety of TIF.
cTIF: A New era of foregut collaboration
The registry also includes one of the largest European datasets on cTIF, a combined procedure in which a laparoscopic hiatal hernia repair is immediately followed by TIF in the same session.
cTIF is designed for reflux patients with hiatal hernias larger than 2 cm, whose symptoms are not fully controlled by medication. It’s ideal for those patients who desire to avoid traditional fundoplication surgery.
By repairing the hernia and reconstructing a flexible valve, cTIF aims to deliver durable reflux control with improved QoL, reduction of medication and lower adverse events than traditional anti reflux surgery. This dataset will help define the role of cTIF in modern reflux pathways and guide patient selection across Europe.
Dr Haidry is internationally recognised as one of the most experienced TIF and cTIF practitioners in Europe. He has:
- Performed hundreds of TIF procedures, placing him among the highest‑volume TIF endoscopists in the region
- Delivered multiple cTIF procedures in partnership with his surgical colleagues at Cleveland Clinic London
- Helped establish TIF and cTIF as safe, effective alternatives for patients seeking long‑term reflux control without lifelong medication or invasive surgery
EURO‑TIF marks a major step forward in defining the future of incisionless and hybrid endoscopic‑surgical therapies for reflux disease and reinforces Dr Haidry’s position as a global leader advancing evidence‑based, minimally invasive solutions for GORD.
The EURO‑TIF dataset is now undergoing detailed statistical analysis. The findings will provide unprecedented insight into real‑world outcomes for TIF and cTIF across Europe and results are expected to be published in 2026.